Home » Newsletters » BioWorld Science

BioWorld Science

Nov. 2, 2009

View Archived Issues

In vivo profile of K-056, a new adenosine A2A antagonist

12-month COMET-1 results show efficacy of CRx-102 in knee osteoarthritis

ADL-5510 reduces levodopa-induced dyskinesia in macaque model of PD

CP-8947, a novel nonsteroidal SPRM, exhibits progestational activity in preclinical study

New antiproliferative compounds disclosed by the European Molecular Biology Laboratory

Abeta production inhibitors claimed by Eisai for the treatment of Alzheimer's disease

Advaxis receives IRB approval for ADXS-11-001 trial in cervical dysplasia

ARYx Therapeutics prepares to outlicense budiodarone, ATI-7505 and tecarfarin

MAP Pharmaceuticals completes interim safety review of phase III Levadex trial

FDA grants emergency use authorization to Gen-Probe's Prodesse ProFlu-ST test for H1N1 flu

Pharmaxis files MAA with EMEA for Bronchitol in cystic fibrosis

FDA issues complete response letter regarding Transcept's NDA for Intermezzo

NasVax reports results from preclinical testing of H1N1 antigen formulated with VaxiSome

Ipsen launches Dysport in U.S. for treatment of cervical dystonia in adults

Eisai and Quintiles sign strategic collaboration agreement to develop six oncology drugs

Health Canada grants product approval for Intercell's Japanese encephalitis vaccine Ixiaro

Novartis Pharma decides not to license Idenix's IDX-184 for hepatitis C

Phase III trial evaluates effects of tolvaptan on kidney volume change in ADPKD

Everolimus/EC-MPS improves renal function in de novo renal transplant patients

Human data available for anti-obesity drug PSN-602

TVPR1 antagonists described by sanofi-aventis as analgesics

Genta reports results from phase III AGENDA trial of Genasense in advanced melanoma

Shire reports results from study of selective alpha-2A agonist Intuniv for ADHD

Celldex Therapeutics reports results from phase I studies of CDX-1307 in advanced epithelial cancers

Hutchison MediPharma starts phase I trial of HMPL-011 for auto-immune disease

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for June 18, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for June 18, 2025.
An early stage 85% remissions rate in AML drives Aptevo’s stock surge
BioWorld
An 85% remissions rate was found in updated results from Aptevo Therapeutics Inc.’s ongoing phase Ib/II Ranier study of mipletamig in one of the toughest blood...
BIO 2025: Makary lays out FDA’s path, launches pilot review program
BioWorld
On the same day that FDA Commissioner Martin Makary spoke in a fireside chat during the 2025 Biotechnology Innovation Organization’s International Convention, the...
Alphadesign: AI creating proteins from scratch
BioWorld Science
The Alphafold machine learning system for predicting a protein’s structure from its amino acid sequence has been adapted to make it possible to design de novo...